

- bodies—Conditions for reconstitution of dimeric IFN- $\gamma$ ,  
 Eur. J. Biochem., 215:481-486 (1993).  
 Welch, "How Cells Respond to Stress", Scientific American,  
 pp. 56-64 (May 1993).  
 5 Wetzel (1994) Trends Biochem. 12, 193-198.  
 Wetzel et al., (1991) Bio/Technol. 9, 731-737.  
 Winter et al., (1994) J. Biol. Chem. 269, 22007-22013.  
 Wisniewski et al., Biochem. Biophys. Res. Commun.,  
 192:359-365 (1993)  
 0 Yankner et al., (1990) Science 250, 279-282.  
 Young et al., (1994).  
 Zhu et al., (1989) Nature 339, 483-484.

✓ What is claimed is:

- 5 1. A method of selecting an anti-aggregation molecule  
 having the chaperone-like activity of anti-aggregation,  
 wherein the anti-aggregation molecule is selected from the  
 group consisting of a monoclonal antibody, a genetically  
 engineered antibody antigen binding fragment, and a single  
 0 chain monoclonal antibody, and wherein said anti-  
 aggregation molecule binds to a bioactive native target  
 polypeptide epitope with a high binding constant and is  
 non-inhibitory to the biological activity of the target  
 polypeptide comprising the steps of:
  - 15 denaturing a target polypeptide which aggregates,  
 mixing the target polypeptide with said anti-aggregation  
 molecule to form a mixture,  
 incubating the mixture under conditions allowing for  
 10 aggregation,  
 selecting non-aggregated mixtures, and  
 testing the nonaggregated target polypeptide coupled to  
 the anti-aggregation molecule for bioactivity thereby  
 selecting an anti-aggregation molecule with the  
 15 chaperone-like activity of anti-aggregation which when  
 coupled to the target polypeptide maintains bioactivity.
  2. The method of claim 1 further characterized by the  
 target polypeptide being  $\beta$ -amyloid.
  - ✓ 3. A method of selecting an anti-aggregation molecule  
 10 having the chaperone-like activity of anti-aggregation,  
 wherein the anti-aggregation molecule is selected from the  
 group consisting of a monoclonal antibody, a genetically  
 engineered antibody antigen binding fragment, and a single  
 15 chain monoclonal antibody, and wherein said anti-  
 aggregation molecule binds to a bioactive native target  
 polypeptide epitope with a high binding constant, reverses  
 aggregation and is non-inhibitory to the biological activity  
 of the target polypeptide comprising the steps of:
    - 20 preparing an aggregated target polypeptide,  
 mixing the target polypeptide with said anti-aggregation  
 molecule to form a mixture,  
 selecting mixtures with non-aggregated target  
 polypeptides, and  
 15 testing the target polypeptide coupled to the anti-  
 aggregation molecule for bioactivity thereby identify-  
 ing an anti-aggregation molecule with the chaperone-  
 like activity of anti-aggregation which when coupled to  
 the target polypeptide maintains bioactivity.
    - 20 4. The method of claim 3 further characterized by the  
 target polypeptide being  $\beta$ -amyloid.

\* \* \* \* \*

add AT  
 add  
 B1

0344140 11590